2-Arahidonilgliceril etar
| 2-Arahidonilgliceril etar | |||
|---|---|---|---|
| |||
| IUPAC ime |
| ||
| Drugi nazivi | 2-AGE, 2-arahidonilgliceril etar, Noladin etar, Noladin | ||
| Identifikacija | |||
| CAS registarski broj | 222723-55-9 | ||
| PubChem[1][2] | 6483057 | ||
| ChemSpider[3] | 4983515 
| ||
| ChEMBL[4] | CHEMBL146346
| ||
| Jmol-3D slike | Slika 1 | ||
| |||
| |||
| Svojstva | |||
| Molekulska formula | C23H40O3 | ||
| Molarna masa | 364,56 g/mol | ||
|
Ukoliko nije drugačije napomenuto, podaci se odnose na standardno stanje (25 °C, 100 kPa) materijala | |||
| Infobox references | |||
2-Arahidonilgliceril etar (2-AGE, Noladinski etar) je endokanabinoid. Njegova izolacija iz svinjskog mozga, strukturno određivanje i sinteza su opisani 2001.[5]
2-AGE se vezuje sa Ki od 21 nM za CB1 receptor[5] i 480 nM za CB2 receptor.[6] On je agonist na oba receptora i parcijalni agonist za TRPV1 kanal.[7] Nakon vezivanja CB2 receptora on inhibira adenilat ciklazu i stimuliše ERK-MAPK.[8] U poređenju sa 2-arahidonoilglicerolom, noladin je metabolički stabilniji, te ima duži poluživot.[9] On snižava intraokularni pritisak,[9] povišava stepen GABA preuzimanja u globus pallidus pacova[10] i ima neuroprotektivno dejstvo.[11]
- ↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519.
- ↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
- ↑ Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846.
- ↑ Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594.
- ↑ 5,0 5,1 Hanus, L.; Abu-Lafi, S.; Fride, E.; Breuer, A.; Vogel, Z.; Shalev, D.; Kustanovich, I.; Mechoulam, R. (2001). „2-Arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor”. Proceedings of the National Academy of Sciences 98 (7): 3662–3665. DOI:10.1073/pnas.061029898. PMC 31108. PMID 11259648.
- ↑ Shoemaker JL, Joseph BK, Ruckle MB, Mayeux PR, Prather PL (2005). „The endocannabinoid noladin ether acts as a full agonist at human CB2 cannabinoid receptors”. J. Pharmacol. Exp. Ther. 314 (2): 868–75. DOI:10.1124/jpet.105.085282. PMID 15901805.
- ↑ Duncan M, Millns P, Smart D, Wright JE, Kendall DA, Ralevic V (2004). „Noladin ether, a putative endocannabinoid, attenuates sensory neurotransmission in the rat isolated mesenteric arterial bed via a non-CB1/CB2 Gi/o linked receptor”. Br. J. Pharmacol. 142 (3): 509–18. DOI:10.1038/sj.bjp.0705789. PMC 1574960. PMID 15148262.
- ↑ Shoemaker JL, Ruckle MB, Mayeux PR, Prather PL (2005). „Agonist-directed trafficking of response by endocannabinoids acting at CB2 receptors”. J. Pharmacol. Exp. Ther. 315 (2): 828–38. DOI:10.1124/jpet.105.089474. PMID 16081674.
- ↑ 9,0 9,1 Laine K, Järvinen K, Mechoulam R, Breuer A, Järvinen T (2002). „Comparison of the enzymatic stability and intraocular pressure effects of 2-arachidonylglycerol and noladin ether, a novel putative endocannabinoid”. Invest. Ophthalmol. Vis. Sci. 43 (10): 3216–22. PMID 12356827.
- ↑ Venderova K, Brown TM, Brotchie JM (2005). „Differential effects of endocannabinoids on [(3)H]-GABA uptake in the rat globus pallidus”. Exp. Neurol. 194 (1): 284–7. DOI:10.1016/j.expneurol.2005.02.012. PMID 15899265.
- ↑ Sun Y, Alexander SP, Garle MJ i dr.. (2007). „Cannabinoid activation of PPARα; a novel neuroprotective mechanism”. Br. J. Pharmacol. 152 (5): 734–43. DOI:10.1038/sj.bjp.0707478. PMC 2190030. PMID 17906680.
